









Markets
/
Stocks
/
nasdaq-rnac
/

Cartesian Therapeutics Inc

RNAC

View Detailed Chart

12.330USD

-0.480-3.75%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

319.79MMarket Cap

LossP/E TTM



Cartesian Therapeutics Inc

12.330

-0.480-3.75%

Overview Company Financials

Financials

Intraday

30m

Today

-3.75%

5 Days

-7.50%

1 Month

+9.99%

6 Months

-38.01%

Year to Date

-31.16%

1 Year

-14.38%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 9 analysts

BUY

Current Rating

36.429

Target Price

195.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Cartesian Therapeutics Inc

RNAC

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(6)

Neutral(3)

Buy(2)

Indicators

Sell(2)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.230

Neutral

RSI(14)

49.781

Neutral

STOCH(KDJ)(9,3,3)

29.072

Sell

ATR(14)

0.946

Low Volatility

CCI(14)

-71.226

Neutral

Williams %R

80.797

Oversold

TRIX(12,20)

0.733

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

13.018

Sell

MA10

12.950

Sell

MA20

12.824

Sell

MA50

11.216

Buy

MA100

11.835

Buy

MA200

15.617

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Ticker SymbolRNAC

CompanyCartesian Therapeutics Inc

CEODr. Carsten Brunn, Ph.D.

Websitehttps://www.cartesiantherapeutics.com/